SCHEMBL12048879

SCHEMBL12048879

CC(C)Oc1ccc(NC(=O)N2CCC(c3ncnc4ccc(C#CCO)cc34)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK7 Q13164 1/20 0.53
PDGFRB P09619 19/20 0.51
KIT P10721 5/20 0.48
FLT3 P36888 5/20 0.48
CSF1R P07333 3/20 0.48
PLK4 O00444 1/20 0.44
GAK O14976 1/20 0.44
EPHB6 O15197 1/20 0.44
STK10 O94804 1/20 0.44
EGFR P00533 1/20 0.44
NTRK1 P04629 1/20 0.44
LCK P06239 1/20 0.44
FGFR1 P11362 1/20 0.44
SRC P12931 1/20 0.44
PDGFRA P16234 1/20 0.44
FLT1 P17948 1/20 0.44
FGFR2 P21802 1/20 0.44
FGFR4 P22455 1/20 0.44
FGFR3 P22607 1/20 0.44
AXL P30530 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12048881 0.90 PDGFRB (0.51) MAPK7PDGFRBKITFLT3CSF1R
SCHEMBL12048877 0.90 MAPK7 (0.49) MAPK7PDGFRBKITFLT3CSF1R
SCHEMBL4963542 0.90 MAPK7 (0.49) MAPK7PDGFRBKITFLT3CSF1R
SCHEMBL12048883 0.89 PDGFRB (0.52) MAPK7PDGFRBKITFLT3CSF1R
SCHEMBL12060839 0.88 MAPK7 (0.54) MAPK7PDGFRBKITFLT3CSF1R
SCHEMBL12049454 0.85 MAPK7 (0.61) MAPK7PDGFRBKITFLT3CSF1R
SCHEMBL14601828 0.85 MAPK7 (0.56) MAPK7PDGFRBKITFLT3CSF1R
SCHEMBL12048872 0.84 MAPK7 (0.56) MAPK7PDGFRBKITFLT3CSF1R
SCHEMBL12060669 0.82 PDGFRB (0.52) MAPK7PDGFRBKITFLT3CSF1R
SCHEMBL12060998 0.82 MAPK7 (0.51) MAPK7PDGFRBKITFLT3CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071768-B2 Alkylquinoline and alkylquinazoline kinase modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2011-12-06 US disclosed
US-20070004660-A1 Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
US-20070004660-A1 Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004660-A1 Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines FLT3, MCL1, CDC42BPG MAPK7 957/4885PDGFRB 224/4885KIT 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.